In a data analysis presented at the American Association for Cancer Research (AACR) Annual Virtual Meeting, held from April 27-28, 2020, researchers suggested that larotrectinib (Vitrakvi) is highly effective in patients with NTRK gene fusions and has demonstrated durable responses.1
However, in patients with other non-fusion NTRK alterations, including point mutations and amplifications, larotrectinib offered only limited benefit.
“NTRK gene fusions are found at high frequencies at 90% or more in rare tumor types such as secretory breast carcinoma and infantile fibrous sarcoma, and at lower frequencies, generally less than 1%, in a range of other common tumor types, including lung and colorectal cancers,” David S. Hong, MD, of the University of Texas MD Anderson Cancer Center, said in a poster presentation of the data at AACR.2
Data for the trial were pooled from 3 clinical…